Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections

International Journal of Antimicrobial Agents

Volumn 44, Issue 5, 2014, Pages 436-442

  Wang, Taotao ^a   Zhu, Huifang ^b   Sun, Jinyao ^a   Cheng, Xiaoliang ^a,c   Xie, Jiao ^a   Dong, Haiyan ^a   Chen, Limei ^a   Wang, Xue ^a   Xing, Jianfeng ^a   Dong, Yalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Tengzhou Central People s Hospital   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

CYP2C19; Efficacy; Hepatotoxicity; Safety; Trough plasma concentrations; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; VORICONAZOLE; ANTIFUNGAL AGENT; CYP2C19 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CYP2C19 GENE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENETIC POLYMORPHISM; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; STEADY STATE; SYSTEMIC MYCOSIS; VISUAL HALLUCINATION; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; FUNGEMIA; GENETICS; MENINGITIS, FUNGAL; MIDDLE AGED; PLASMA; TOXIC HEPATITIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CYTOCHROME P-450 CYP2C19; DRUG-INDUCED LIVER INJURY; FEMALE; FUNGEMIA; HUMANS; MALE; MENINGITIS, FUNGAL; MIDDLE AGED; PLASMA; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; VORICONAZOLE; YOUNG ADULT;

EID: 84908394037     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.07.013     Document Type: Article

References (30)

1. U. Theuretzbacher, F. Ihle, and H. Derendorf Pharmacokinetic/pharmacodynamic profile of voriconazole Clin Pharmacokinet 45 2006 649 663
2. M.M. Azofra, J.L. Somovilla, M.C. Porras, L.H. Carrillo, and R.D. Pérez Use of intralesional voriconazole for the treatment of cutaneous Scedosporium apiospermum infection Clin Infect Dis 51 2010 255 257
3. G.R. Thompson 3rd, and J.S. Lewis 2nd Pharmacology and clinical use of voriconazole Expert Opin Drug Metab Toxicol 6 2010 83 94
4. A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 2008 201 211
5. K. Matsumoto, K. Ikawa, K. Abematsu, N. Fukunaga, K. Nishida, and T. Fukamizu Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes Int J Antimicrob Agents 34 2009 91 94
6. Y. Hamada, Y. Seto, K. Yago, and M. Kuroyama Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis J Infect Chemother 18 2012 501 507
7. M.J. Dolton, J.E. Ray, S.C. Chen, K. Ng, L.G. Pont, and A.J. McLachlan Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring Antimicrob Agents Chemother 56 2012 4793 4799
8. S. Lee, B. Kim, W. Nam, S. Yoon, J. Cho, and S. Shin Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers J Clin Pharmacol 52 2012 195 203
9. Z. Racil, J. Winterova, M. Kouba, P. Zak, L. Malaskova, and L. Buresova Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience Mycoses 55 2012 483 492
10. R. Hyland, B.C. Jones, and D.A. Smith Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole Drug Metab Dispos 31 2003 540 547
11. G. Mikus, I. Scholz, and J. Weiss Pharmacogenomics of the triazole antifungal agent voriconazole Pharmacogenomics 12 2011 861 872
12. M. Berge, R. Guillemain, D.A. Tregouet, C. Amrein, V. Boussaud, and P. Chevalier Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients Eur J Clin Pharmacol 67 2011 253 260
13. T. Wang, S. Chen, J. Sun, J. Cai, X. Cheng, and H. Dong Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections J Antimicrob Chemother 69 2014 463 470
14. B. De Pauw, T.J. Walsh, J.P. Donnelly, D.A. Stevens, J.E. Edwards, and T. Calandra Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 2008 1813 1821
15. W.B. Park, N.H. Kim, K.H. Kim, S.H. Lee, W.S. Nam, and S.H. Yoon The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial Clin Infect Dis 55 2012 1080 1087
16. A. Pascual, C. Csajka, T. Buclin, S. Bolay, J. Bille, and T. Calandra Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections Clin Infect Dis 55 2012 381 390
17. P. Liu, G. Foster, K. Gandelman, R.R. LaBadie, M.J. Allison, and M.J. Gutierrez Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects Antimicrob Agents Chemother 51 2007 3617 3626
18. L. Purkins, N. Wood, K. Greenhalgh, M.J. Allen, and S.D. Oliver Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety Br J Clin Pharmacol 56 Suppl. 1 2003 10 16
19. L. Purkins, N. Wood, K. Greenhalgh, M.D. Eve, S.D. Oliver, and D. Nichols The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent Br J Clin Pharmacol 56 Suppl. 1 2003 2 9
20. X.Z. Zhang, X.E. Huang, Y.L. Xu, X.Q. Zhang, A.L. Su, and Z.S. Shen Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis Asian Pac J Cancer Prev 13 2012 2415 2418
21. K. Ueda, Y. Nannya, K. Kumano, A. Hangaishi, T. Takahashi, and Y. Imai Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders Int J Hematol 89 2009 592 599
22. S.H. Kim, D.S. Yim, S.M. Choi, J.C. Kwon, S. Han, and D.G. Lee Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients Int J Infect Dis 15 2011 e753 e758
23. M. Mallie, J.M. Bastide, A. Blancard, A. Bonnin, S. Bretagne, and M. Cambon In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study Int J Antimicrob Agents 25 2005 321 328
24. Y. Ikeda, K. Umemura, K. Kondo, K. Sekiguchi, S. Miyoshi, and M. Nakashima Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status Clin Pharmacol Ther 75 2004 587 588
25. M. Kimura, Y. Yamagishi, N. Kawasumi, M. Hagihara, T. Hasegawa, and H. Mikamo Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene Jpn J Antibiot 63 2010 255 264
26. C. Eiden, M. Cociglio, D. Hillaire-Buys, S. Eymard-Duvernay, P. Ceballos, and N. Fegueux Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring Xenobiotica 40 2010 701 706
27. M.D. Levin, J.G. den Hollander, B. van der Holt, B.J. Rijnders, M. van Vliet, and P. Sonneveld Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms J Antimicrob Chemother 60 2007 1104 1107
28. L.J. Zuo, T. Guo, D.Y. Xia, and L.H. Jia Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations Genet Test Mol Biomark 16 2012 102 108
29. H.Y. Shi, J. Yan, W.H. Zhu, G.P. Yang, Z.R. Tan, and W.H. Wu Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism Eur J Clin Pharmacol 66 2010 1131 1136
30. I.B. Bondareva, R.W. Jelliffe, O.V. Andreeva, and K.I. Bondareva Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy J Clin Pharm Ther 36 2011 625 636